Details checkedStrong evidenceCheckedtrial

Rincell-1 by Rinri Therapeutics

Also known as: Rincell-1, R1-25

Rinri Therapeutics

Primary source

Company

Rinri Therapeutics

Program Type

Therapeutic

Modality

Cell Therapy

Stage

Phase 1/2

Status

Active

Target Gene

—

Route / Mode

Implantable intracochlear cell transplant

Confidence

92%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-05-31

Geography

United Kingdom

Population

adult, age-related, auditory-neuropathy

Trial IDs

Mechanism

Laboratory-grown otic neural progenitors are implanted with cochlear implantation to regenerate auditory neurons and re-establish cochlear neural signaling.

Indications

Hearing Loss Sensorineural Hearing Loss Age-Related Hearing Loss Auditory Neuropathy

Notes

Most advanced dedicated auditory-neuron replacement program in Europe; first-in-human status makes it strategically important even before efficacy data.

Evidence & Sources

3 structured sources

company

Supports: canonicalName, aliases, company, mechanism, indications, route, populationTags

IDs: Rincell-1

Open

company

Supports: stage, status, notes

IDs: Rincell-1

Open

manual

Supports: trialIds, populationTags, geography